CoChat

Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab

Open access
D'Angelo, Sandra P., Shoushtari, Alexander N., Keohan, Mary Louise, Dickson, Mark A., Gounder, Mrinal M., Chi, Ping, Loo, Jennifer K., Gaffney, Leigh, Schneider, Lee, Patel, Zarine, Erinjeri, Joseph Patrick, Bluth, Mark J., Sjoberg, Ana, Streicher, Howard, Takebe, Naoko, Qin, Li-Xuan, Antonescu, Cristina, DeMatteo, Ronald P., Carvajal, Richard D., Tap, William D. · 2017 · Clinical Cancer Research
Cited by 131

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: A phase Ib study of dasatinib plus ipilimumab in patients with gastrointestinal stromal tumor (GIST) and other sarcomas was performed on the basis of preclinical data demonstrating that combined KIT and CTLA-4 blockade is synergistic. Experimental Design: A standard 3 + 3 design was used to evaluate the safety, efficacy, and immune correlates of treatment. Dose escalation cohorts received ipilimumab 10 or 3 mg/kg every 3 weeks, followed by maintenance every 12 weeks with escalating doses of dasatinib (70 mg daily, 100 mg daily, or 70 mg twice daily). Response was assessed by RECIST 1.1, Choi, and immune-related RECIST criteria (irRC). Results: A total of 28 patients (17 male) were enrolled. Histologic subtypes included GISTs (n = 20) and other sarcomas (n = 8.) Dasatinib 70 mg/day with ipilimumab 10 mg/kg or dasatinib 140 mg/day with ipilimumab 3 mg/kg can be safely administered. Dose-limiting toxicities included grade 3 gastric hemorrhage and anemia. No partial or complete responses were noted by RECIST or irRC. There were 7 of 13 partial responses in the GIST patients by Choi criteria, and 3 of 13 patients each had stable and progressive disease, respectively. Conclusions: Dasatinib and ipilimumab can be safely administered to GIST and sarcoma patients. However, dasatinib was not synergistic with ipilimumab, as there was limited clinical efficacy with the combination. This limited cohort provides prospective data that indoleamine-2,3-dioxygenase (IDO) suppression may potentially correlate with antitumor efficacy in GIST. Given the small cohort, it is only hypothesis generating and additional data would be required. In the era of more modern and effective checkpoint inhibitors, next steps could be consideration of tyrosine kinase inhibitors or IDO inhibitors in combination with anti-PD-1 therapy. Clin Cancer Res; 23(12); 2972–80. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2349

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 131

Metadata

Authors
D'Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z., Erinjeri, J. P., Bluth, M. J., Sjoberg, A., Streicher, H., Takebe, N., Qin, L.-X., Antonescu, C., DeMatteo, R. P., Carvajal, R. D., & Tap, W. D.
Venue
Clinical Cancer Research
Published
2017-06-14
Volume
23
Issue
12
Pages
2972-2980
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2566021721
Cited by
131
References
6
FWCI
12.55
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2349
The paper
D'Angelo, S. P., Shoushtari, A. N., Keohan, M. L., Dickson, M. A., Gounder, M. M., Chi, P., Loo, J. K., Gaffney, L., Schneider, L., Patel, Z., Erinjeri, J. P., Bluth, M. J., Sjoberg, A., Streicher, H., Takebe, N., Qin, L.-X., Antonescu, C., DeMatteo, R. P., Carvajal, R. D., & Tap, W. D. (2017). Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.